Stevanato Group SpA

STVN · NYSE

$19.01−$0.01 (−0.05%)TodayMarket closed · Oct 20, 7:00 PM ET

Prev close $19.02

Latest news

Press releaseOct 20, 4:30 PM ETBusiness Wire
Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026
Press releaseSep 8, 4:05 PM ETBusiness Wire
Stevanato Group to Participate in Two Upcoming Investor Conferences
NewsAug 4, 9:36 AM ET
Stevanato Group Q2 2026 Earnings Call: Complete Transcript
NewsAug 4, 6:30 AM ET
Stevanato Gr Q2 Adj. EPS $0.16 Beats $0.14 Estimate, Sales $351.091M Miss $351.370M Estimate
Press releaseAug 4, 6:30 AM ETBusiness Wire
Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026
NewsJul 30, 6:38 AM ET
Stevanato Group Says Liraglutide-Based Combination Products Incorporating Its Proprietary Alina Pen Injector Platform Receives Marketing Authorizations In Europe
Press releaseJul 30, 6:30 AM ETBusiness Wire
Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries
Press releaseJul 21, 6:30 AM ETBusiness Wire
Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026
Press releaseJun 8, 6:30 AM ETBusiness Wire
Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management
Press releaseJun 3, 5:45 PM ETBusiness Wire
Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting
NewsMay 7, 6:31 AM ET
Stevanato Gr Q1 Adj. EPS $0.13 Beats $0.12 Estimate, Sales $320.386M Beat $312.910M Estimate
Press releaseMay 7, 6:30 AM ETBusiness Wire
Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026
Press releaseMay 4, 5:45 PM ETBusiness Wire
Stevanato Group to Participate in Three Upcoming Investor Conferences
Press releaseApr 23, 4:05 PM ETBusiness Wire
Stevanato Group to Report First Quarter 2026 Financial Results on May 7, 2026
Press releaseMar 12, 4:45 PM ETBusiness Wire
Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum
NewsMar 4, 6:34 AM ET
Stevanato Group: Q4 Earnings Insights
NewsMar 4, 6:33 AM ET
Stevanato Gr Q4 Adj. EPS $0.21 Beats $0.20 Estimate, Sales $403.378M Beat $384.320M Estimate
Press releaseMar 4, 6:30 AM ETBusiness Wire
Stevanato Group Delivers 7% Revenue Growth (9% at Constant Currency) for Fiscal Year 2025, Including Record Revenue from High-Value Solutions and Expanded Margins
NewsMar 4, 6:11 AM ET
Earnings Scheduled For March 4, 2026
NewsMar 3, 10:01 AM ET
Exploring Stevanato Gr's Earnings Expectations
Press releaseFeb 19, 6:30 AM ETBusiness Wire
Stevanato Group to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 4, 2026
Press releaseNov 6, 6:30 AM ETBusiness Wire
Stevanato Group Reports Revenue of €303.2 Million for the Third Quarter of 2025
NewsNov 6, 6:12 AM ET
Earnings Scheduled For November 6, 2025
Press releaseOct 31, 7:30 AM ETBusiness Wire
Stevanato Group to Participate in Upcoming Investor Conferences
Press releaseOct 22, 6:30 AM ETBusiness Wire
Stevanato Group to Report Third Quarter 2025 Financial Results on November 6, 2025
Press releaseOct 21, 6:30 AM ETBusiness Wire
Stevanato Group Expands Drug Delivery Systems Capacity to Strengthen Global Integrated Offerings
Press releaseSep 2, 5:59 PM ETBusiness Wire
Stevanato Group to Participate in Upcoming Investor Conferences
Press releaseAug 5, 6:30 AM ETBusiness Wire
Stevanato Group Reports Revenue of €280.0 Million for the Second Quarter of 2025
NewsAug 5, 4:32 AM ET
Earnings Scheduled For August 5, 2025
Press releaseJul 23, 6:30 AM ETBusiness Wire
Stevanato Group Secures €200 Million in Financing from BNL BNP Paribas, Cassa Depositi e Prestiti, and Banco BPM to Fund Ongoing CAPEX Investments in Italy and the U.S.
Press releaseJul 22, 4:30 PM ETBusiness Wire
Stevanato Group to Report Second Quarter 2025 Financial Results on August 5, 2025
Press releaseMay 9, 4:03 PM ETBusiness Wire
Stevanato Group to Participate in Upcoming Investor Conferences
Press releaseMay 8, 6:37 AM ETBusiness Wire
Stevanato Group Reports Revenue of €256.6 Million for the First Quarter of 2025
NewsMay 8, 4:33 AM ET
Earnings Scheduled For May 8, 2025
Press releaseApr 24, 5:15 PM ETBusiness Wire
Stevanato Group to Report First Quarter 2025 Financial Results on May 8, 2025
Press releaseMar 11, 4:30 PM ETBusiness Wire
Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum
NewsDec 31, 8:47 AM ETAvi Kapoor
Sangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026

Stevanato Group to Participate in Two Upcoming Investor Conferences

Stevanato Group Q2 2026 Earnings Call: Complete Transcript

Stevanato Gr Q2 Adj. EPS $0.16 Beats $0.14 Estimate, Sales $351.091M Miss $351.370M Estimate

Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

Stevanato Group Says Liraglutide-Based Combination Products Incorporating Its Proprietary Alina Pen Injector Platform Receives Marketing Authorizations In Europe

Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries

Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026

Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management

Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting

Stevanato Gr Q1 Adj. EPS $0.13 Beats $0.12 Estimate, Sales $320.386M Beat $312.910M Estimate

Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026

Stevanato Group to Participate in Three Upcoming Investor Conferences

Stevanato Group to Report First Quarter 2026 Financial Results on May 7, 2026

Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum

Stevanato Group: Q4 Earnings Insights

Stevanato Gr Q4 Adj. EPS $0.21 Beats $0.20 Estimate, Sales $403.378M Beat $384.320M Estimate

Stevanato Group Delivers 7% Revenue Growth (9% at Constant Currency) for Fiscal Year 2025, Including Record Revenue from High-Value Solutions and Expanded Margins

Earnings Scheduled For March 4, 2026

Exploring Stevanato Gr's Earnings Expectations

Stevanato Group to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 4, 2026

Stevanato Group Reports Revenue of €303.2 Million for the Third Quarter of 2025

Earnings Scheduled For November 6, 2025

Stevanato Group to Participate in Upcoming Investor Conferences

Stevanato Group to Report Third Quarter 2025 Financial Results on November 6, 2025

Stevanato Group Expands Drug Delivery Systems Capacity to Strengthen Global Integrated Offerings

Stevanato Group to Participate in Upcoming Investor Conferences

Stevanato Group Reports Revenue of €280.0 Million for the Second Quarter of 2025

Earnings Scheduled For August 5, 2025

Stevanato Group Secures €200 Million in Financing from BNL BNP Paribas, Cassa Depositi e Prestiti, and Banco BPM to Fund Ongoing CAPEX Investments in Italy and the U.S.

Stevanato Group to Report Second Quarter 2025 Financial Results on August 5, 2025

Stevanato Group to Participate in Upcoming Investor Conferences

Stevanato Group Reports Revenue of €256.6 Million for the First Quarter of 2025

Earnings Scheduled For May 8, 2025

Stevanato Group to Report First Quarter 2025 Financial Results on May 8, 2025

Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum

Sangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session